-
1
-
-
33847328289
-
The Bcl-2 apoptotic switch in cancer development and therapy
-
DOI 10.1038/sj.onc.1210220, PII 1210220
-
Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337. doi:10.1038/sj.onc.1210220. PubMed: 17322918. (Pubitemid 46328466)
-
(2007)
Oncogene
, vol.26
, Issue.9
, pp. 1324-1337
-
-
Adams, J.M.1
Cory, S.2
-
2
-
-
36849030243
-
Management of Metastatic Melanoma
-
DOI 10.1053/j.seminoncol.2007.09.008, PII S0093775407001844, Malignant Melanoma
-
Tawbi HA, Kirkwood JM (2007) Management of metastatic melanoma. Semin Oncol 34: 532-545. doi:10.1053/j.seminoncol.2007.09.008. PubMed: 18083377. (Pubitemid 350236308)
-
(2007)
Seminars in Oncology
, vol.34
, Issue.6
, pp. 532-545
-
-
Tawbi, H.A.1
Kirkwood, J.M.2
-
3
-
-
33747878462
-
Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model
-
DOI 10.1016/S0074-7696(06)51004-6, PII S0074769606510046, A Survey of Cell Biology
-
Hersey P, Zhuang L, Zhang XD (2006) Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251: 131-158. doi:10.1016/S0074-7696(06)51004-6. PubMed: 16939779. (Pubitemid 44291415)
-
(2006)
International Review of Cytology
, vol.251
, pp. 131-158
-
-
Hersey, P.1
Zhuang, L.2
Zhang, X.D.3
-
4
-
-
0038793948
-
Apoptosis and melanoma chemoresistance
-
DOI 10.1038/sj.onc.1206454, Melanoma
-
Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151. doi:10.1038/sj.onc.1206454. PubMed: 12789290. (Pubitemid 36713766)
-
(2003)
Oncogene
, vol.22
, Issue.20
, pp. 3138-3151
-
-
Soengas, M.S.1
Lowe, S.W.2
-
5
-
-
0038439258
-
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria
-
DOI 10.1038/sj.onc.1206427
-
Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869-2881. doi:10.1038/sj.onc.1206427. PubMed: 12771938. (Pubitemid 36648914)
-
(2003)
Oncogene
, vol.22
, Issue.19
, pp. 2869-2881
-
-
Zhang, X.D.1
Borrow, J.M.2
Zhang, X.Y.3
Nguyen, T.4
Hersey, P.5
-
6
-
-
35448958407
-
Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis
-
DOI 10.1158/0008-5472.CAN-07-2047
-
Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA et al. (2007) Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 67: 9750-9761. doi: 10.1158/0008-5472.CAN- 07-2047. PubMed: 17942905. (Pubitemid 47621222)
-
(2007)
Cancer Research
, vol.67
, Issue.20
, pp. 9750-9761
-
-
Chen, C.J.1
Li, H.C.2
Gillespie, S.3
Yu, F.W.4
Kiejda, K.A.5
Xu, D.Z.6
Hersey, P.7
-
7
-
-
53049105459
-
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress
-
doi: 10.1158/0008-5472.CAN-08-0349. PubMed: 18701495
-
Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE et al. (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68: 6708-6717. doi: 10.1158/0008-5472.CAN-08-0349. PubMed: 18701495.
-
(2008)
Cancer Res
, vol.68
, pp. 6708-6717
-
-
Jiang, C.C.1
Lucas, K.2
Avery-Kiejda, K.A.3
Wade, M.4
DeBock, C.E.5
-
8
-
-
37849012616
-
Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells
-
doi: 10.1097/CAD.0b013e3282f3138a. PubMed: 18176116
-
Zhu BK, Wang P, Zhang XD, Jiang CC, Chen LH et al. (2008) Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anticancer Drugs 19: 189-200. doi: 10.1097/CAD.0b013e3282f3138a. PubMed: 18176116.
-
(2008)
Anticancer Drugs
, vol.19
, pp. 189-200
-
-
Zhu, B.K.1
Wang, P.2
Zhang, X.D.3
Jiang, C.C.4
Chen, L.H.5
-
9
-
-
34548011015
-
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins
-
DOI 10.1038/sj.cdd.4402163, PII 4402163
-
Wolter KG, Verhaegen M, Fernández Y, Nikolovska-Coleska Z, Riblett M et al. (2007) Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14: 1605-1616. doi:10.1038/sj.cdd.4402163. PubMed: 17541428. (Pubitemid 47278846)
-
(2007)
Cell Death and Differentiation
, vol.14
, Issue.9
, pp. 1605-1616
-
-
Wolter, K.G.1
Verhaegen, M.2
Fernandez, Y.3
Nikolovska-Coleska, Z.4
Riblett, M.5
Martin De La, V.C.6
Wang, S.7
Soengas, M.S.8
-
10
-
-
44049083639
-
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy?
-
doi:10.1038/cdd.2008.37. PubMed: 18369371
-
Labi V, Grespi F, Baumgartner F, Villunger A (2008) Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 15: 977-987. doi:10.1038/cdd.2008.37. PubMed: 18369371.
-
(2008)
Cell Death Differ
, vol.15
, pp. 977-987
-
-
Labi, V.1
Grespi, F.2
Baumgartner, F.3
Villunger, A.4
-
11
-
-
33750834023
-
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
-
doi:10.1016/j.ccr.2006.08.027. PubMed: 17097561
-
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399. doi:10.1016/j.ccr.2006.08.027. PubMed: 17097561.
-
(2006)
Cancer Cell
, vol.10
, pp. 389-399
-
-
Van Delft, M.F.1
Wei, A.H.2
Mason, K.D.3
Vandenberg, C.J.4
Chen, L.5
-
12
-
-
34249996230
-
L inhibitor ABT-737
-
DOI 10.1038/sj.onc.1210166, PII 1210166
-
Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972-3979. doi:10.1038/sj.onc.1210166. PubMed: 17173063. (Pubitemid 46884293)
-
(2007)
Oncogene
, vol.26
, Issue.27
, pp. 3972-3979
-
-
Lin, X.1
Morgan-Lappe, S.2
Huang, X.3
Li, L.4
Zakula, D.M.5
Vernetti, L.A.6
Fesik, S.W.7
Shen, Y.8
-
13
-
-
33846674886
-
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation
-
DOI 10.1158/0008-5472.CAN-06-3964
-
Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791. doi:10.1158/0008-5472.CAN-06-3964. PubMed: 17234790. (Pubitemid 46192219)
-
(2007)
Cancer Research
, vol.67
, Issue.2
, pp. 782-791
-
-
Chen, S.1
Dai, Y.2
Harada, H.3
Dent, P.4
Grant, S.5
-
14
-
-
33845797913
-
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
-
DOI 10.1158/0008-5472.CAN-06-1748
-
Verhaegen M, Bauer JA, Martín de la Vega C, Wang G, Wolter KG et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359. doi:10.1158/0008-5472.CAN-06-1748. PubMed: 17145881. (Pubitemid 46009966)
-
(2006)
Cancer Research
, vol.66
, Issue.23
, pp. 11348-11359
-
-
Verhaegen, M.1
Bauer, J.A.2
De La, V.C.M.3
Wang, G.4
Wolter, K.G.5
Brenner, J.C.6
Nikolovska-Coleska, Z.7
Bengtson, A.8
Nair, R.9
Elder, J.T.10
Van Brocklin, M.11
Carey, T.E.12
Bradford, C.R.13
Wang, S.14
Soengas, M.S.15
-
15
-
-
34247529341
-
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1
-
DOI 10.1158/1078-0432.CCR-06-1574
-
Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S et al. (2007) Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13: 2226-2235. doi:10.1158/1078-0432.CCR-06- 1574. PubMed: 17404107. (Pubitemid 46649892)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.7
, pp. 2226-2235
-
-
Mohammad, R.M.1
Goustin, A.S.2
Aboukameel, A.3
Chen, B.4
Banerjee, S.5
Wang, G.6
Nikolovska-Coleska, Z.7
Wang, S.8
Al-Katib, A.9
-
16
-
-
34248362003
-
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
-
DOI 10.1182/blood-2006-07-034173
-
Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109: 4441-4449. doi:10.1182/blood-2006-07-034173. PubMed: 17227835. (Pubitemid 46743414)
-
(2007)
Blood
, vol.109
, Issue.10
, pp. 4441-4449
-
-
Perez-Galan, P.1
Roue, G.2
Villamor, N.3
Campo, E.4
Colomer, D.5
-
17
-
-
37249057877
-
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells
-
DOI 10.1007/s00280-007-0499-3
-
Li J, Viallet J, Haura EB (2008) A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 61: 525-534. doi:10.1007/s00280-007-0499-3. PubMed: 17505826. (Pubitemid 350275989)
-
(2008)
Cancer Chemotherapy and Pharmacology
, vol.61
, Issue.3
, pp. 525-534
-
-
Li, J.1
Viallet, J.2
Haura, E.B.3
-
18
-
-
34249982915
-
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
-
DOI 10.1182/blood-2006-10-047951
-
Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY et al. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438. doi:10.1182/blood-2006-10-047951. PubMed: 17332241. (Pubitemid 46890566)
-
(2007)
Blood
, vol.109
, Issue.12
, pp. 5430-5438
-
-
Trudel, S.1
Zhi, H.L.2
Rauw, J.3
Tiedemann, R.E.4
Xiao, Y.W.5
Stewart, A.K.6
-
19
-
-
84876260453
-
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
-
PubMed: 23515850
-
Goard CA, Schimmer AD (2013) An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid 8: 15-26. PubMed: 23515850.
-
(2013)
Core Evid
, vol.8
, pp. 15-26
-
-
Goard, C.A.1
Schimmer, A.D.2
-
20
-
-
84878254063
-
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia
-
doi:10.1182/blood-2012-04-425033. PubMed: 23393050
-
Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW et al. (2013) Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 121: 2689-2703. doi:10.1182/blood- 2012-04-425033. PubMed: 23393050.
-
(2013)
Blood
, vol.121
, pp. 2689-2703
-
-
Urtishak, K.A.1
Edwards, A.Y.2
Wang, L.S.3
Hudome, A.4
Robinson, B.W.5
-
21
-
-
37649023004
-
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
-
doi:10.1073/pnas.0709443104. PubMed: 18040043
-
Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104: 19512-19517. doi:10.1073/pnas.0709443104. PubMed: 18040043.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 19512-19517
-
-
Nguyen, M.1
Marcellus, R.C.2
Roulston, A.3
Watson, M.4
Serfass, L.5
-
22
-
-
84878207972
-
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1
-
doi:10.1016/j.exphem.2013.02.002. PubMed: 23416210
-
Bosman MC, Schuringa JJ, Quax WJ, Vellenga E (2013) Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. Exp Hematol 41: 530-538. doi:10.1016/j.exphem.2013.02.002. PubMed: 23416210.
-
(2013)
Exp Hematol
, vol.41
, pp. 530-538
-
-
Bosman, M.C.1
Schuringa, J.J.2
Quax, W.J.3
Vellenga, E.4
-
23
-
-
44849133234
-
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
-
doi:10.1158/0008-5472.CAN-07-1919. PubMed: 18451169. Available online at: doi:10.1158/0008-5472.CAN-07-1919 Available online at: PubMed: 18451169
-
Konopleva M, Watt J, Contractor R, Tsao T, Harris D et al. (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68: 3413-3420. doi:10.1158/0008-5472.CAN-07- 1919. PubMed: 18451169. Available online at: doi:10.1158/0008-5472.CAN-07-1919 Available online at: PubMed: 18451169
-
(2008)
Cancer Res
, vol.68
, pp. 3413-3420
-
-
Konopleva, M.1
Watt, J.2
Contractor, R.3
Tsao, T.4
Harris, D.5
-
24
-
-
33644747383
-
Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin
-
DOI 10.1158/1078-0432.CCR-05-2084
-
Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 12: 1355-1364. doi:10.1158/1078-0432.CCR-05-2084. PubMed: 16489094. (Pubitemid 43342529)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.4
, pp. 1355-1364
-
-
Zhang, X.D.1
Wu, J.J.2
Gillespie, S.3
Borrow, J.4
Hersey, P.5
-
25
-
-
0038413866
-
Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: Pigmentation marker, ultrastructural and UV-survival studies
-
DOI 10.1034/j.1600-0749.2003.00033.x
-
Leonard JH, Marks LH, Chen W, Cook AL, Boyle GM et al. (2003) Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies. Pigment Cell Res 16: 198-207. doi:10.1034/j.1600-0749.2003.00033.x. PubMed: 12753386. (Pubitemid 36597055)
-
(2003)
Pigment Cell Research
, vol.16
, Issue.3
, pp. 198-207
-
-
Leonard, J.H.1
Marks, L.H.2
Chen, W.3
Cook, A.L.4
Boyle, G.M.5
Smit, D.J.6
Brown, D.L.7
Stow, J.L.8
Parsons, P.G.9
Sturm, R.A.10
-
26
-
-
0035291880
-
Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
-
Nguyen T, Zhang XD, Hersey P (2001) Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 7: 966s-973s. PubMed: 11300498. (Pubitemid 33600952)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.11 SUPPL.
-
-
Nguyen, T.1
Zhang, X.D.2
Hersey, P.3
-
27
-
-
0013583837
-
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
-
Zhang XD, Franco A, Myers K, Gray C, Nguyen T et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753. PubMed: 10364001. (Pubitemid 29269125)
-
(1999)
Cancer Research
, vol.59
, Issue.11
, pp. 2747-2753
-
-
Zhang, X.D.1
Franco, A.2
Myers, K.3
Gray, C.4
Nguyen, T.5
Hersey, P.6
-
28
-
-
74049087498
-
2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2
-
doi:10.1158/1535-7163.TARG-09-C122. PubMed: 20003459
-
Liu H, Jiang CC, Lavis CJ, Croft A, Dong L et al. (2009) 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer 8: 122. doi:10.1158/1535-7163.TARG-09-C122. PubMed: 20003459.
-
(2009)
Mol Cancer
, vol.8
, pp. 122
-
-
Liu, H.1
Jiang, C.C.2
Lavis, C.J.3
Croft, A.4
Dong, L.5
-
29
-
-
53049105459
-
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress
-
doi: 10.1158/0008-5472.CAN-08-0349. PubMed: 18701495
-
Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE et al. (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68: 6708-6717. doi: 10.1158/0008-5472.CAN-08-0349. PubMed: 18701495.
-
(2008)
Cancer Res
, vol.68
, pp. 6708-6717
-
-
Jiang, C.C.1
Lucas, K.2
Avery-Kiejda, K.A.3
Wade, M.4
DeBock, C.E.5
-
30
-
-
66149128392
-
Bcl-2 family on guard at the ER
-
PubMed: 19279228
-
Szegezdi E, Macdonald DC, Ní Chonghaile T, Gupta S, Samali A (2009) Bcl-2 family on guard at the ER. Am J Physiol Cell Physiol 296: C941-C953. PubMed: 19279228.
-
(2009)
Am J Physiol Cell Physiol
, vol.296
-
-
Szegezdi, E.1
Macdonald, D.C.2
Ní Chonghaile, T.3
Gupta, S.4
Samali, A.5
-
32
-
-
69249139451
-
Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax
-
PubMed: 19724688
-
Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD (2009) Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 11: 945-955. PubMed: 19724688.
-
(2009)
Neoplasia
, vol.11
, pp. 945-955
-
-
Jiang, C.C.1
Wroblewski, D.2
Yang, F.3
Hersey, P.4
Zhang, X.D.5
-
33
-
-
58849086028
-
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells
-
doi:10.1158/1078-0432.CCR-08-1575. PubMed: 19118042
-
Huang S, Okumura K, Sinicrope FA (2009) BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 15: 150-159. doi:10.1158/1078-0432.CCR-08-1575. PubMed: 19118042.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 150-159
-
-
Huang, S.1
Okumura, K.2
Sinicrope, F.A.3
-
34
-
-
84893193187
-
Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes
-
PubMed: 23744296
-
Basit F, Cristofanon S, Fulda S (2013) Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ 7: 45. PubMed: 23744296.
-
(2013)
Cell Death Differ
, vol.7
, pp. 45
-
-
Basit, F.1
Cristofanon, S.2
Fulda, S.3
-
35
-
-
80052074729
-
Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress
-
doi: 10.1038/onc.2011.87. PubMed: 21423203
-
Dong L, Jiang CC, Thorne RF, Croft A, Yang F et al. (2011) Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 30: 3716-3726. doi: 10.1038/onc.2011.87. PubMed: 21423203.
-
(2011)
Oncogene
, vol.30
, pp. 3716-3726
-
-
Dong, L.1
Jiang, C.C.2
Thorne, R.F.3
Croft, A.4
Yang, F.5
-
36
-
-
35848969791
-
ER stress signaling and the BCL-2 family of proteins: From adaptation to irreversible cellular damage
-
doi:10.1089/ars.2007.1793. PubMed: 17854276
-
Hetz CA (2007) ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage. Antioxid Redox Signal 9: 2345-2355. doi:10.1089/ars.2007.1793. PubMed: 17854276.
-
(2007)
Antioxid Redox Signal
, vol.9
, pp. 2345-2355
-
-
Hetz, C.A.1
-
37
-
-
79953306808
-
Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival
-
doi:10.1016/j.molcel.2011.02.009. PubMed: 21353614
-
Elgendy M, Sheridan C, Brumatti G, Martin SJ (2011) Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell 42: 23-35. doi:10.1016/j.molcel.2011.02.009. PubMed: 21353614.
-
(2011)
Mol Cell
, vol.42
, pp. 23-35
-
-
Elgendy, M.1
Sheridan, C.2
Brumatti, G.3
Martin, S.J.4
-
38
-
-
84858788427
-
Obatoclax and Lapatinib Interact to Induce Toxic Autophagy Through NOXA
-
PubMed: 22219388
-
Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S et al. (2012) Obatoclax and Lapatinib Interact to Induce Toxic Autophagy Through NOXA. Mol Pharmacol, 81: 527-40. PubMed: 22219388.
-
(2012)
Mol Pharmacol
, vol.81
, pp. 527-540
-
-
Tang, Y.1
Hamed, H.A.2
Cruickshanks, N.3
Fisher, P.B.4
Grant, S.5
-
39
-
-
84876492939
-
GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells
-
doi: 10.1158/1535-7163.MCT-12-0617. PubMed: 23395885
-
Schwartz-Roberts JL, Shajahan AN, Cook KL, Wärri A, Abu-Asab M et al. (2013) GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 12: 448-459. doi: 10.1158/1535-7163.MCT-12-0617. PubMed: 23395885.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 448-459
-
-
Schwartz-Roberts, J.L.1
Shajahan, A.N.2
Cook, K.L.3
Wärri, A.4
Abu-Asab, M.5
-
40
-
-
33745872296
-
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins
-
DOI 10.1038/sj.cdd.4401937, PII 4401937
-
Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421. doi:10.1038/sj.cdd.4401937. PubMed: 16645636. (Pubitemid 44057478)
-
(2006)
Cell Death and Differentiation
, vol.13
, Issue.8
, pp. 1419-1421
-
-
Zhai, D.1
Jin, C.2
Satterthwait, A.C.3
Reed, J.C.4
-
41
-
-
33947598446
-
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
-
DOI 10.1038/modpathol.3800750, PII 3800750
-
Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD et al. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 20: 416-426. doi:10.1038/modpathol.3800750. PubMed: 17384650. (Pubitemid 46482365)
-
(2007)
Modern Pathology
, vol.20
, Issue.4
, pp. 416-426
-
-
Zhuang, L.1
Lee, C.S.2
Scolyer, R.A.3
McCarthy, S.W.4
Zhang, X.D.5
Thompson, J.F.6
Hersey, P.7
-
42
-
-
53349097246
-
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
-
doi: 10.1158/1535-7163.MCT-08-0285. PubMed: 18723481
-
Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ (2008) BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 7: 2339-2347. doi: 10.1158/1535-7163.MCT-08-0285. PubMed: 18723481.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2339-2347
-
-
Mott, J.L.1
Bronk, S.F.2
Mesa, R.A.3
Kaufmann, S.H.4
Gores, G.J.5
-
43
-
-
67549141546
-
Different forms of cell death induced by putative BCL2 inhibitors
-
doi:10.1038/cdd.2009.48. PubMed: 19390557
-
Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K et al. (2009) Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16: 1030-1039. doi:10.1038/cdd.2009.48. PubMed: 19390557.
-
(2009)
Cell Death Differ
, vol.16
, pp. 1030-1039
-
-
Vogler, M.1
Weber, K.2
Dinsdale, D.3
Schmitz, I.4
Schulze-Osthoff, K.5
|